Peptides for Hepatitis C: Direct-Acting Antivirals and Immunomodulators

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies are being explored for Hepatitis C as direct-acting antivirals and immunomodulators, aiming to inhibit viral replication and enhance host immune responses. These targeted interventions offer potential to improve treatment outcomes and achieve sustained virologic response in HCV patients.

Peptides for Hepatitis C: A New Era in Antiviral Therapy

Hepatitis C virus (HCV) infection is a major global health concern, often leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma. While direct-acting antiviral (DAA) medications have revolutionized HCV treatment, achieving high cure rates, there remains a need for alternative or complementary therapies, especially for patients with treatment failures or specific contraindications. Peptide-based therapies are emerging as a promising avenue, offering novel mechanisms to directly inhibit the virus or modulate the host immune response.

Peptide-Based Strategies to Combat HCV

Peptides are being developed to target various stages of the HCV life cycle, from entry into host cells to viral replication and assembly.

1. Direct Antiviral Peptides

• Blocking Viral Entry: Peptides can interfere with the initial steps of HCV infection. For instance, the E2-42 peptide has been shown to inhibit HCV entry by binding to the E1 and E2 glycoproteins, crucial for viral attachment and fusion [2, 10]. Similarly, a novel human radixin peptide (Peptide1) can specifically block HCV infection [1].
• Inhibiting Viral Replication: Researchers have identified cell-permeable peptides that inhibit specific HCV proteins, thereby blocking viral replication [6, 8]. Peptides derived from the N-terminal amphipathic α-helix of HCV NS5A also exhibit antiviral activity by disrupting liposomes, suggesting a role in inhibiting viral assembly [12].
• Disrupting Viral Particles: Some peptides, like those found in scorpion venom (e.g., Ctry2459-H2 and Ctry2459-H3), possess antiviral activity against HCV by directly disrupting viral particles [3]. This virocidal action can prevent both de novo infection and suppress ongoing infection [13].

2. Immune-Modulating Peptides

• Therapeutic Vaccines: Peptide vaccines aim to stimulate a robust and specific immune response against HCV. The novel peptide vaccine IC41, for example, consists of synthetic peptides harboring HCV T cell epitopes and has shown promise in inducing HCV-specific immune responses in patients [4, 9, 11].
• Broad Immune Enhancement: Immune-active peptides, including those derived from the thymus, have been explored for their general immune-enhancing effects in chronic viral hepatitis, which could indirectly benefit HCV patients [7].

Clinical Outlook and Practical Advice

The development of peptide-based therapies for Hepatitis C is an active area of research, with several candidates showing promise in preclinical and early clinical studies. These therapies could offer new options for patients, potentially overcoming resistance to existing DAAs or providing alternatives for those who cannot tolerate current treatments.

Practical Takeaway

If you have Hepatitis C, it's vital to consult with your gastroenterologist or hepatologist to discuss the most effective treatment plan for your specific genotype and disease stage. While DAA therapies are highly effective, staying informed about ongoing research into peptide-based treatments can provide insight into future therapeutic possibilities, especially if current options are not suitable or successful for you.

References

[1] Li, Y., et al. (2014). A Novel Human Radixin Peptide Inhibits Hepatitis C Virus Infection by Targeting the E1/E2 Glycoprotein Complex. PLoS ONE, 9(10), e110221. https://pmc.ncbi.nlm.nih.gov/articles/PMC4217309/
[2] Yin, P., et al. (2017). A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting the E1/E2 glycoprotein complex. Scientific Reports, 7(1), 3866. https://www.nature.com/articles/s41598-017-04274-8
[3] Zhang, R., et al. (2022). Natural or synthetic defense peptides against HBV and HCV infections. Frontiers in Microbiology, 13, 9701303. https://pmc.ncbi.nlm.nih.gov/articles/PMC9701303/
[4] Klade, C. S., et al. (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus vaccine IC41 in patients with chronic hepatitis C. Vaccine, 24(22), 4834-4842. https://www.sciencedirect.com/science/article/abs/pii/S0264410X06002738
[5] Naylor, P. H., et al. (2007). Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) monotherapy in HIV-infected patients. Journal of Clinical Virology, 39(4), 307-310. https://pubmed.ncbi.nlm.nih.gov/17803064/
[6] ScienceDaily. (2012). Researchers identify cell-permeable peptide that inhibits hepatitis C. https://www.sciencedaily.com/releases/2012/01/120131092458.htm
[7] Pisi, E., et al. (1996). Thymus-derived peptides in the treatment of viral chronic hepatitis. Immunopharmacology and Immunotoxicology, 18(4), 579-592. https://pubmed.ncbi.nlm.nih.gov/9030468/
[8] UCLA Health. (2026). UCLA researchers identify peptide that inhibits replication of hepatitis C. https://www.uclahealth.org/news/release/ucla-researchers-identify-peptide
[9] Yutani, S., et al. (2007). Phase I clinical study of a personalized peptide vaccination for patients with chronic hepatitis C. Vaccine, 25(40), 6987-6995. https://www.sciencedirect.com/science/article/abs/pii/S0264410X0700919X
[10] Yin, P., et al. (2017). A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting the E1/E2 glycoprotein complex. PMC, 5479846. https://pmc.ncbi.nlm.nih.gov/articles/PMC5479846/
[11] Klade, C. S., et al. (2008). Therapeutic Vaccination of Chronic Hepatitis C Patients With the IC41 Vaccine. Gastroenterology, 134(5), 1342-1351. https://www.gastrojournal.org/article/S0016-5085(08)00346-6/abstract00346-6/abstract)
[12] Lee, Y., et al. (2024). Inhibitory peptides derived from Hepatitis C virus NS5A for antiviral activity. Journal of Biological Chemistry, 299(7), 104868. https://pubmed.ncbi.nlm.nih.gov/39389166/
[13] Brass, V., et al. (2008). A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection. Proceedings of the National Academy of Sciences, 105(31), 11030-11035. https://www.pnas.org/doi/10.1073/pnas.0712380105